The AREDS
Story

In 1995, Bausch + Lomb collaborated for a clinical trial with government researchers at the National Eye Institute. The goal: To see if a high dose nutrient formula can help people with Age-related Macular Degeneration (AMD).

20 Years of AMD Leadership

2001: The First Age
Related Eye Disease
Study (AREDS)

NEI researchers concluded their first
five-year clinical Age Related Eye Disease
Study (AREDS)

4,757

Study participants ages 55 to 80 years, with and without AMD.

19%

Reduced risk of moderate vision loss after five years.

25%

Reduction in risk of AMO progression in those with moderate to advanced AMO.

10Years

Participants showed continued effects at study follow-up in 2006.

2013: AREDS2, the 2nd Age Related Eye Disease Study

Based on new learnings around AMD, the
NEI researchers sought to improve the
original AREDS formula.

4,203

Study participants ages 50 to 85, with AMD.

82

Clinical centers across the U.S.

5 Years

Length of AREDS2 study.

18%

Reduced risk of progressing to advanced AMD, compared to patients taking the original AREDS formulation.1

1. No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis.

Today

The NEI recommends the AREDS 2 formula for helping to reduce the risk of progression in moderate to advanced AMD.

Talk to your doctor to determine if the AREDS 2 formula is right for you.

Nutrient Amount (per day) Percent Daily Value
Zinc 80 mg 540%
Lutein 10 mg **
Zeaxanthin 2 mg **
Vitamin C 500 mg 840%
Vitamin E 180 mg 1200%
Copper 2 mg 100%

* Percent Daily Values (DV) Based on a 2000-calorie diet
**Daily Value not established

Stay Tuned

The National Eye Institute is working on its report on the AREDS 2 10-year
follow-up study, and we'll be announcing the results soon.

Your Comprehensive Resource for AMD

Information. Support. Savings.

Learn Eye-healthy
Lifestyle Changes

Expert Tips

PreserVision
Coupons

Visit SightMatters.com

by Bausch + Lomb

Text Size:A−A+